GL1X · GenesisL1 explorer

MolNFT v1 · #180464 · protein

Monobody 12VC3 bound to HRAS(WT)

7L0F · GTPase HRAS: “Monobody 12VC3 bound to HRAS(WT)”. X-ray diffraction, 2 ligands (GSP, MG), 15 pockets (best druggability 0.86). MolNFT v1 #180464 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
7L0F
Type
protein
Length
1,037 residues
Chains
8
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase HRAS; Monobody 12VC3
EC
3.6.5.2
UniProt
P01112
Ligands
GSP, MG
Pockets
15 · best druggability 0.86

Structure

x-ray diffraction · 3 distinct chains · 17% helix, 44% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
E, A, G, LGTPase HRAS (EC 3.6.5.2)protein16637% helix, 27% strandP01112
F, B, MMonobody 12VC3protein930% helix, 59% strand—
HMonobody 12VC3protein940% helix, 59% strand—

Ligands and binding sites

  • GSP · 5'-guanosine-diphosphate-monothiophosphate · ligand · 4 copies · chains E, F, A, B, G, H, L, M
  • MG · Magnesium ion · metal · 4 copies · chains E, A, G, L

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

15 pockets found on a 1 Å grid, 6 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111970.860.87120MG, GSP
23140.760.8848MG, GSP
34770.730.8243empty
45410.730.8157empty
52740.690.8445MG, GSP

Interfaces

10 interfaces between chains.

  • A–B · 911 Ų buried · 13 hydrogen bonds · protein-protein
  • E–F · 904 Ų buried · 14 hydrogen bonds · protein-protein
  • G–H · 897 Ų buried · 14 hydrogen bonds · protein-protein
  • L–M · 887 Ų buried · 13 hydrogen bonds · protein-protein
  • A–G · 676 Ų buried · 9 hydrogen bonds · protein-protein

Compared structures

  • 7L0F · Monobody 12VC3 Bound to HRAS(WT) · the same entry in another collection · chain E against E, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.